Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis

被引：40
|
作者：
Cottrell, Mackenzie L. [1 ]
Prince, Heather M. A. [2 ]
Schauer, Amanda P. [1 ]
Sykes, Craig [1 ]
Maffuid, Kaitlyn [1 ]
Poliseno, Amanda [1 ]
Chun, Tae-Wook [3 ]
Huiting, Erin [3 ]
Stanczyk, Frank Z. [4 ]
Peery, Anne F. [5 ]
Dellon, Evan S. [5 ]
Adams, Jessica L. [6 ,7 ]
Gay, Cindy [2 ]
Kashuba, Angela D. M. [1 ,2 ]
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Div Infect Dis, Sch Med, Chapel Hill, NC 27515 USA
[3] NIAID, HIV Immunovirol Unit, 9000 Rockville Pike, Bethesda, MD 20892 USA
[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[5] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA
[6] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA
[7] Cooper Univ Hosp, Early Intervent Program, Camden, NJ USA
来源：
CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷 / 12期
基金：
美国国家卫生研究院;
关键词：
transgender; preexposure prophylaxis; lower gastrointestinal tract; HIV; feminizing hormone therapy; HIV; WOMEN; NUCLEOTIDE;
D O I：
10.1093/cid/ciz290
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (rho = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy.
引用
收藏
页码：2201 / 2204
页数：4
相关论文
共 50 条
  • [41] An Opportunity Too Good to Miss Implementing Human Immunodeficiency Virus Preexposure Prophylaxis in Sexually Transmitted Diseases Clinics
    Marx, Grace E.
    Bhatia, Ramona
    Rietmeijer, Cornelis A.
    SEXUALLY TRANSMITTED DISEASES, 2016, 43 (04) : 266 - 267
  • [42] Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis
    Colby, Donn J.
    Kroon, Eugene
    Sacdalan, Carlo
    Gandhi, Monica
    Grant, Robert M.
    Phanuphak, Praphan
    Ananworanich, Jintanat
    Robb, Merlin L.
    Phanuphak, Nittaya
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (06) : 962 - 964
  • [43] Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety
    Solas, Caroline
    Bregigeon, Sylvie
    Faucher-Zaegel, Olivia
    Quaranta, Sylvie
    Obry-Roguet, Veronique
    Tamalet, Catherine
    Lacarelle, Bruno
    Poizot-Martin, Isabelle
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (02) : 404 - 409
  • [44] High Human Immunodeficiency Virus Incidence in a Cohort of Rwandan Female Sex Workers
    Braunstein, Sarah L.
    Ingabire, Chantal M.
    Kestelyn, Evelyne
    Uwizera, Aline Umutoni
    Mwamarangwe, Lambert
    Ntirushwa, Justin
    Nash, Denis
    Veldhuijzen, Nienke J.
    Nel, Annalene
    Vyankandondera, Joseph
    van de Wijgert, Janneke H. H. M.
    SEXUALLY TRANSMITTED DISEASES, 2011, 38 (05) : 385 - 394
  • [45] Low Human Immunodeficiency Virus (HIV) Testing Rates and No HIV Preexposure Prophylaxis Prescribed Among Female Patients Diagnosed With a Sexually Transmitted Infection, 2017-2018
    Henny, Kirk D.
    Huang, Ya-Lin A.
    Hoover, Karen W.
    OBSTETRICS AND GYNECOLOGY, 2020, 136 (06): : 1083 - 1085
  • [46] Iowa TelePrEP: A Public-Health-Partnered Telehealth Model for Human Immunodeficiency Virus Preexposure Prophylaxis Delivery in a Rural State
    Hoth, Angela B.
    Shafer, Cody
    Dillon, Dena Behm
    Mayer, Randy
    Walton, George
    Ohl, Michael E.
    SEXUALLY TRANSMITTED DISEASES, 2019, 46 (08) : 507 - 512
  • [47] Early Adopters of Human Immunodeficiency Virus Preexposure Prophylaxis in a Population-based Combination Prevention Study in Rural Kenya and Uganda
    Koss, Catherine A.
    Ayieko, James
    Mwangwa, Florence
    Owaraganise, Asiphas
    Kwarisiima, Dalsone
    Balzer, Laura B.
    Plenty, Albert
    Sang, Norton
    Kabami, Jane
    Ruel, Theodore D.
    Black, Douglas
    Camlin, Carol S.
    Cohen, Craig R.
    Bukusi, Elizabeth A.
    Clark, Tamara D.
    Charlebois, Edwin D.
    Petersen, Maya L.
    Kamya, Moses R.
    Havlir, Diane V.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (12) : 1853 - 1860
  • [48] Correlations Between Human Immunodeficiency Virus (HIV) Infection and Rectal Gonorrhea Incidence in Men Who Have Sex With Men: Implications for Future HIV Preexposure Prophylaxis Trials
    Mullick, Charu
    Murray, Jeffrey
    JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (02): : 214 - 217
  • [49] Global Human Immunodeficiency Virus Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis
    Sharma, Ishani
    Hill, Andrew
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (02) : 386 - 394
  • [50] Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus
    Purdy, Julia B.
    Gafni, Rachel I.
    Reynolds, James C.
    Zeichner, Steven
    Hazra, Rohan
    JOURNAL OF PEDIATRICS, 2008, 152 (04): : 582 - 584
12345